Y-mAbs Therapeutics (YMAB) Misses Q4 EPS by 58c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q4 EPS of ($1.28), $0.58 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $9.6 million versus the consensus estimate of $10.82 million.

The Company had approximately $181.6 million in cash and cash equivalents as of December 31, 2021.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• Abercrombie & Fitch (ANF) Tops Q2 EPS by $2.19, Offers Guidance
• Dycom Industries (DY) Tops Q2 EPS by 59c, Beats on Revenue
• HSBC Upgrades Bank of East Asia (23:HK) (BKEAY) to Buy